Goldman Sachs’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $148K | Sell |
92,368
-11,156
| -11% | -$17.9K | ﹤0.01% | 4805 |
|
|
2025
Q1 | $126K | Buy |
103,524
+44,063
| +74% | +$53.8K | ﹤0.01% | 4775 |
|
|
2024
Q4 | $112K | Buy |
59,461
+23,887
| +67% | +$45.1K | ﹤0.01% | 4759 |
|
|
2024
Q3 | $190K | Buy |
+35,574
| New | +$190K | ﹤0.01% | 4506 |
|
|
2024
Q1 | – | Sell |
-2,767
| Closed | -$21.8K | – | 4875 |
|
|
2023
Q4 | $21.8K | Sell |
2,767
-295
| -10% | -$2.32K | ﹤0.01% | 4605 |
|
|
2023
Q3 | $13.5K | Sell |
3,062
-3,569
| -54% | -$15.8K | ﹤0.01% | 4592 |
|
|
2023
Q2 | $231K | Buy |
6,631
+3,080
| +87% | +$107K | ﹤0.01% | 4340 |
|
|
2023
Q1 | $77.4K | Sell |
3,551
-5,826
| -62% | -$127K | ﹤0.01% | 4705 |
|
|
2022
Q4 | $203K | Buy |
9,377
+4,643
| +98% | +$100K | ﹤0.01% | 4498 |
|
|
2022
Q3 | $115K | Sell |
4,734
-529
| -10% | -$12.9K | ﹤0.01% | 4887 |
|
|
2022
Q2 | $107K | Sell |
5,263
-1,643
| -24% | -$33.4K | ﹤0.01% | 5094 |
|
|
2022
Q1 | $246K | Buy |
6,906
+1,340
| +24% | +$47.7K | ﹤0.01% | 4985 |
|
|
2021
Q4 | $152K | Sell |
5,566
-1,990
| -26% | -$54.3K | ﹤0.01% | 5094 |
|
|
2021
Q3 | $328K | Buy |
7,556
+7,027
| +1,328% | +$305K | ﹤0.01% | 4609 |
|
|
2021
Q2 | $26K | Sell |
529
-3,785
| -88% | -$186K | ﹤0.01% | 5304 |
|
|
2021
Q1 | $194K | Buy |
4,314
+2,023
| +88% | +$91K | ﹤0.01% | 4855 |
|
|
2020
Q4 | $60K | Sell |
2,291
-1,575
| -41% | -$41.2K | ﹤0.01% | 4535 |
|
|
2020
Q3 | $56K | Buy |
+3,866
| New | +$56K | ﹤0.01% | 4313 |
|
|
2017
Q1 | – | Sell |
-811
| Closed | -$390K | – | 4499 |
|
|
2016
Q4 | $390K | Sell |
811
-6
| -0.7% | -$2.89K | ﹤0.01% | 3589 |
|
|
2016
Q3 | $555K | Buy |
+817
| New | +$555K | ﹤0.01% | 3380 |
|